(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
Exhibit Number | Description | ||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
RECURSION PHARMACEUTICALS, INC. | ||||||||
By: | /s/ Christopher Gibson | |||||||
Christopher Gibson | ||||||||
Chief Executive Officer | ||||||||
Cover |
Jan. 13, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | May 25, 2023 |
Entity Registrant Name | RECURSION PHARMACEUTICALS, INC. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-40323 |
Entity Tax Identification Number | 46-4099738 |
Entity Address, Address Line One | 41 S Rio Grande Street |
Entity Address, City or Town | Salt Lake City, |
Entity Address, State or Province | UT |
Entity Address, Postal Zip Code | 84101 |
City Area Code | 385 |
Local Phone Number | 269 - 0203 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Class A Common Stock, par value $0.00001 per share |
Trading Symbol | RXRX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001601830 |
Amendment Flag | false |
-8?20$3;8T.P
M6BP^0"X99K>]9!:G
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end